Meta AnalysisID 2623
强心苷类与前列腺癌风险：观察性研究的系统评价与Meta分析
CRD42016052110
Cardiac glycosides are used to treat heart failure and supra-ventricular arrhythmias and are reported to be associated with estrogen-sensitive cancers such as breast cancer or uterus cancer. However, reports on the assoc
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2623
- Evidence Id
- 11181
- Core Evidence Id
- 11181
- Source Meta Analysis Id
- 2574
- Herb2 Meta Analysis Id
- HBMA002574
- Crd Id
- CRD42016052110
- Title
- Cardiac glycosides and the risk of prostate cancer: a systematic review and meta-analysis of observational studies
- Review Question
- Cardiac glycosides are used to treat heart failure and supra-ventricular arrhythmias and are reported to be associated with estrogen-sensitive cancers such as breast cancer or uterus cancer. However, reports on the association between cardiac glycoside use and prostate cancer risk have been inconsistent. We aimed to investigate the association between cardiac glycoside use and prostate cancer risk by conducting a meta-analysis of case-control and cohort studies.
- Study Type Included
- Observational studies (case-control, nested case-control or cohort studies).
- Condition Being Studied
- Cardiac glycosides (digoxin and digitalis) are phytoestrogens and are frequently used in clinical settings. Some estrogen-sensitive cancers such as breast cancer and uterus cancer have been reported to be linked to the use of cardiac glycosides. However, evidence on the association between cardiac glycoside use and prostate cancer risk have been inconsistent. We aimed, therefore, to perform a meta-analysis to explore this association.
- Participant
- 1. Age >=18 years old; 2. Without the diagnosis of prostate cancer.
- Animal
- Human Disease Modelled
- Intervention
- Participants who use cardiac glycoside medication.
- Comparator Control
- Participants who do not use cardiac glycosides.
- Main Outcome
- The risk of prostate cancer.
- Outcome Measure
- Additional Outcome
- None.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Cardiac Glycosides; Drug-Related Side Effects and Adverse Reactions; Humans; Long Term Adverse Effects; Male; Prostatic Neoplasms; Risk; Risk Factors; Treatment Outcome
- Contact
- Hedong Han [email protected]
- Organisational Affiliation
- Department of Health Statistics, Second Military Medical University
- Funding Source
- This study was conducted under a grant from the National Nature Science Foundation of China (81373105) and the Fourth Round of the Three-year Action Plan on Public Health Discipline and Talent Program: Evidence-based Public Health and Health Economics (No. 15GWZK0901).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2016-11-23
- Anticipated Start Date
- 2016-11-23
- Anticipated Completion Date
- 2017-04-30
- Title Cn
- 强心苷类与前列腺癌风险：观察性研究的系统评价与Meta分析
- Title En
- Cardiac glycosides and the risk of prostate cancer: a systematic review and meta-analysis of observational studies
- Bilingual Status
- complete